Rescuers in China were drilling new shafts on Thursday to reach miners trapped underground for 11 days following an explosion, including one they hope to use to bring the survivors back to safety. Rescuers have been in contact with 11 miners trapped in the middle section of the mine, about 350 metres underground, and have managed to send food and medical supplies down to them. One miner is known to have died of injuries sustained in the initial blast, state media reported on Wednesday.
The family of a French-Irish teenager will challenge an inquest ruling that she died by misadventure after vanishing in the Malaysian jungle while on holiday, their lawyer said Thursday.
As the January transfer window enters its final stretch, Europe's top clubs are sitting tight with financial restraints exacerbated by the coronavirus pandemic leading to a downturn in player movement worldwide.
Aussie F1 star Daniel Ricciardo is hopeful the Australian Open will be a guiding light for the postponed Australian GP.
(Bloomberg) -- China’s three biggest telecommunications firms said they requested a review of the New York Stock Exchange’s decision to delist their shares more than a week ago, a move triggered by an executive order issued by former U.S. President Donald Trump.The drama surrounding the delisting, which played out over a few days with the bourse at one point reversing the decision before enforcing it again, caused wild swings in the companies’ stock as investors were left with little time to react to the various moves. It also prompted some global equity indexes to remove the securities.In separate filings Thursday to the Hong Kong Stock Exchange -- where they’re also listed -- China Mobile Ltd., China Unicom Hong Kong Ltd. and China Telecom Corp. said that written requests had been filed with the NYSE and that they’d also asked for trading suspensions to be stayed while the review is undertaken. The review will be scheduled at least 25 business days from the date the request is filed, the statements said. There’s no assurance the review request will be successful, the companies added.In its communications around the delistings, the NYSE indicated it was acting to comply with an executive order issued by Trump, barring investments in companies deemed by the U.S. to be linked to China’s military. The ambiguously worded order was part of Trump’s effort to punish China in the waning days of his presidency.The announcement of the review requests came hours after Joe Biden was sworn in as Trump’s successor in Washington on Wednesday.The former administration had been ramping up its attacks on China the past few months, imposing sanctions over human-rights abuses and in response to the nation’s crackdown on Hong Kong. The U.S. had also sought to sever economic links and deny Chinese firms access to American capital, an escalation of its moves over tariffs as part of the trade war. China’s role in the coronavirus pandemic, which has hit the U.S. more than anywhere else, hardened the Trump administration’s position against the country and its bid to become a global leader.The three companies lost more than $30 billion in market value in the final weeks of 2020 as investors pulled back from their shares following Trump’s November order. They then shed billions more after the delistings. Subsequently, they have rebounded at least 12% in Hong Kong trading since Jan. 8, supported by a record inflow of cash from the mainland.China Mobile gained 0.3% as of 11:42 a.m. Hong Kong Thursday, while China Telecom fell 2.2%. China Unicom slipped 1%. The telecommunications companies advised investors to “exercise caution” when dealing in their securities.(Updates with Hong Kong traded shares in eighth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
A Sydney landlord set the scene with a chain bike lock and acted his way through a fake phone call during a shakedown he compared to Quentin Tarantino's films.
Taiwan's de facto ambassador to the US was formally invited to President Joe Biden's inauguration in what Taipei on Thursday said was a precedent-setting first since Washington switched recognition to Beijing in 1979.
The former first lady changed into a Gucci dress and walked straight to a waiting car.
Virus experts believe hosting the Tokyo Games may be too big a gamble with the pandemic forcing Japan into a state of emergency.
Glancy Prongay & Murray LLP ("GPM"), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Pauwels v. Bit Digital, Inc, et al., (Case No. 1:21-cv-00515) on behalf of persons and entities that purchased or otherwise acquired Bit Digital, Inc. ("Bit Digital" or the "Company") (NASDAQ: BTBT) securities between December 21, 2020 and January 8, 2021, inclusive (the "Class Period"). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act").
There are merits to claiming benefits at any of these ages, so the question is which one is right for you.
Aston Villa fans were left stunned after Man City scored a contentious goal when it appeared Rodri was clearly offside.
NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Lizhi Inc. (NASDAQ: LIZI) pursuant and/or traceable to Lizhi’s January 17, 2020 initial public offering (the “IPO” or the “Offering”). The lawsuit seeks to recover damages for Lizhi investors under the federal securities laws. To join the Lizhi class action, go http://www.rosenlegal.com/cases-register-1986.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action. According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) at the time of the IPO, the coronavirus was already ravaging China, the home base, principal market, and significant hub for Lizhi, its employees, and its customers; (2) the complications associated with the coronavirus were already negatively affecting Lizhi’s business, as employees and customers contracted the virus, lost employment, or otherwise experienced difficulty in generating, publishing, and monetizing the content critical to Lizhi’s platform; (3) even prior to the IPO, Lizhi employees and customers complained of, and to, Lizhi, which harmed the Company’s reputation and financial condition and prospects; and (4) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1986.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 firstname.lastname@example.org email@example.com firstname.lastname@example.org www.rosenlegal.com
CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds from the offering are expected to be approximately $231.0 million. Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on or about January 25, 2021, subject to customary closing conditions. J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Cowen and Credit Suisse are acting as book-runners. An automatically effective shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 12, 2018. The offering is being made only by means of a prospectus and prospectus supplement that form part of the registration statement. A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC and is available at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement may be obtained by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at email@example.com, or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at firstname.lastname@example.org. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Editas MedicineAs a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision gene medicines for a broad class of diseases. Forward-Looking StatementsThis press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 including statements about the anticipated closing of the offering. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally; uncertainties inherent in the initiation of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Editas Medicine’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the SEC on November 6, 2020, the Company’s preliminary prospectus filed with the SEC on January 19, 2021, and other filings the Company may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: Contacts Media: Cristi Barnett (617) 401-0113 email@example.com Investors: Editas Medicine Investor Relations (617) 401-9052 firstname.lastname@example.org
Victorian Labor stalwarts Steve Bracks and Jenny Macklin scolded former state minister Marlene Kairouz for her initial answers to their branch-stacking audit.
An Adairs shopper wasn't pleased when she opened up her package after it was delivered by Australia Post.
US President Joe Biden has moved to scrap the controversial Keystone XL oil pipeline, revoking its permit hours after being sworn in.
Asian stocks rose to new record highs on Thursday, tracking U.S. markets as investors hoped for more economic stimulus from newly inaugurated U.S. President Joe Biden to offset damage wreaked by the COVID-19 pandemic. Republicans in the U.S. Congress have indicated they are willing to work with the new president on his administration's top priority, a $1.9 trillion U.S. fiscal stimulus plan, but some are opposed to the plan's price tag. Democrats took control of the U.S. Senate on Wednesday, but will still need Republican support to pass the program.
(Bloomberg) -- Investors in mainland China are showing unprecedented interest in Hong Kong stocks, powering the city’s fastest rally for a new year in more than three decades.Mainland traders have net purchased about $27 billion worth of Hong Kong shares in January alone, nearing a third what they bought in all of last year. Keyword searches and references for “Hong Kong stocks” on Tuesday reached 6.3 million on WeChat, China’s most popular instant-messaging tool, seven times the amount at the end of December, according to app data.Inflows from north of the border picked up earlier this month after a U.S. ban on some Chinese securities forced international investors to dump the likes of China Mobile Ltd. at bargain prices. Mainland buyers swooped in, broadening their targets after extreme valuations onshore encouraged a rotation into Hong Kong’s cheaper shares.The result is a booming stock market in a city whose economy is still reeling from the effects of the pandemic and anti-government protests. The benchmark Hang Seng Index has gained 10% this year -- about three times the advance of the MSCI All-Country World Index -- for its best start since 1985. The Hang Seng Index rose past 30,000 points on Thursday, the first time it breached that level since May 2019. By 11:00 a.m., it traded up 0.5% to 30,110.53 points, boosted in part by Tencent Holdings Ltd. rallying 2.6% to a record high.At least three brokerages said they’ve seen a surge in demand for Hong Kong stocks in recent weeks. Applications for new accounts jumped 50% last weekend at TF International Securities Group Ltd., according to Zhu Yunpeng, head of the firm’s securities and futures brokerage department in Shenzhen. The intense interest prompted the China Securities Journal to warn stock valuations could become disconnected from reality, leading to a correction.Li Changmin, managing director at Snowball Wealth in Guangzhou, increased exposure of Hong Kong stocks to about 20% of total holdings from “very little” before last week. Li bought Chinese brokerages that were as much as 40% cheaper than their mainland shares.“Hong Kong stocks have always been cheaper, but previously you might have had to wait a long time for other buyers to follow,” Li said. “Now things are different because of the greater power of southbound flows.”Yuan-denominated shares are on average 21% more expensive than their H-share equivalents, according to an index going back to 2006. The premium was at an 11-year high of almost 50% in October. Cheap stocks in Hong Kong last year meant southbound flows were already at a record, picking up in March as the Hang Seng Index traded below book value. But the speed and scale of purchases in January is unlike any period since the second link opened in 2016 with Shenzhen.Traders in mainland China have limited options when it comes to asset allocation, as capital controls restrict their access to overseas securities. At home, Chinese families are moving more of their money into stock funds after rock-bottom interest-rates, a purge of peer-to-peer lending platforms and stagnant property prices in large cities left them with poor returns elsewhere.But professional investors are all buying the same large caps, increasing concentration risk in the stock market and pushing valuations for the popular consumer-staples sector to the priciest since 2008. Mutual funds invested about two-thirds of their assets in only 100 stocks, according to the latest available data.For some shares, southbound inflow comprises the majority of trading, accounting for 94% of China Mobile’s total turnover year-to-date and 74% for CNOOC Ltd., Morgan Stanley strategists Laura Wang, Jonathan Garner and Fran Chen wrote in a Jan. 19 report. That compares to 2% and 3% in 2020, respectively, they wrote.Along with valuations, Hong Kong’s stock market also has the strong backing of Beijing. The Communist Party has been pushing the city as an alternative to New York as a fundraising center for Chinese firms. At more than $50 billion, the amount of capital raised in Hong Kong from initial public offerings and secondary listings last year was the most in a decade, largely from Chinese companies.Still, for some money managers, the recent run-up has a familiar feel to it. Mainland funds bought in early 2018 and in March last year, only for investors to be disappointed when Hong Kong’s stock market lagged.“The sad reality is no one is able to hold on to Hong Kong stocks for long, whether it be 2015 when gains were driven by retail investors, or 2018 when it was due to foreign funds,” said He Qi, a fund manager at Huatai Pinebridge Fund Management Co. He said the rally may have another two months to go before reversing. “The lesson is to quit while you’re ahead, don’t wait till things really get crazy.”(Updates with HSI price and Tencent record)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
A decade after Egypt's mass protests briefly unlocked new freedoms, human rights groups say it is back to square one as President Abdel Fattah al-Sisi has stamped out all opposition.